Salmeterol (CAS 89365-50-4) — formula C25H37NO4, molecular weight 415.6; category organic chemicals.
| CAS Number | 89365-50-4 |
|---|---|
| Molecular Formula | C25H37NO4 |
| Molecular Weight | 415.6 |
| Melting Point | 75.5-76.5 °C |
| Boiling Point | 603 |
| LogP | 4.2 |
| Applications | Uses: Anti-asthmatic, Xinafoate salt, Bronchodilator, MEDICATION, Salmeterol ..., is, indicated as bronchodilators for the treatment of bronchospasm associated with chronic obstructive airway disease, including bronchitis and pulmonary emphysema. ..., Included in US product labeling, Use (kg, approx.) in Germany (2009): >10, Use (kg) in USA (2002): 67800, Consumption (g per capita, approx.) in Germany (2009): 0.000122, Consumption (g per capita) in the USA (2002): 0.24, Calculated removal (%): 73.4, For the treatment of asthma and chronic obstructive pulmonary disease (COPD)., Use Classification: Pharmaceuticals, Methods of Manufacturing: Preparation: I.F. Skidmore et al., DE 3414752, eidem US 4992474 (1984, 1991 both to Glaxo), Formulations, Preparations: Oral Inhalation: Aerosol 21 ug (of salmeterol) per metered spray (from the actuator) Serevent ( with fluorochlorohydrocarbon propellants), (GlaxoSmithKline), Powder: 50 ug (of salmeterol) per inhalation Serevent Diskus, (GlaxoSmithKline)., Salmeterol xinafoate, Oral Inhalation: Powder 50 ug (of salmeterol) with fluticasone propionate 100, 250, or 500 ug per inhalation- Advair (GlaxoSmithKline)., Salmeterol xinafoate combinations, General Manufacturing Information: Structural analog of albuterol., Information available in 2005 indicated that Salmeterol was used in the manufacture of pharmaceutical preparations in the following countries: Antigua & Barbuda, Aruba, Bahrain, Barbados, Chile, Croatia, Grenada, Guyana, India, Iran, Jamaica, Kuwait, Luxembourg, Netherlands Antilles, Oman, Qatar, Saint Lucia, Saint Vincent & The Grenadines, Slovenia, Turkey, Trinidad & Tobago, United Arab Emirates, Yugoslavia (1, 2), Information available in 2005 indicated that Salmeterol xinafoate was used in the manufacture of pharmaceutical preparations in the following countries: Algeria, Argentina, Australia, Austria, Bangladesh, Belgium, Brazil, Bulgaria, Canada, Costa Rica, Czech Republic, Denmark, Dominican Republic, Ecuador, El Salvador, Finland, France, Germany, Greece, Guatemala, Honduras, Hong Kong, Hungary, Indonesia, Ireland, Israel, Italy, Malaysia, Mexico, Netherlands, New Zealand, Nicaragua, Norway, Panama, Poland, Portugal, Romania, Russian Federation, Singapore, South Africa, Spain, Sweden, Switzerland, Thailand, United Kingdom, United States (1 |
| Category | Organic Chemicals |
Documented applications: Uses: Anti-asthmatic, Xinafoate salt, Bronchodilator, MEDICATION, Salmeterol ..., is, indicated as bronchodilators for the treatment of bronchospasm associated with chronic obstructive airway disease, including bronchitis and pulmonary emphysema. ..., Included in US product labeling, Use (kg, approx.) in Germany (2009): >10, Use (kg) in USA (2002): 67800, Consumption (g per capita, approx.) in Germany (2009): 0.000122, Consumption (g per capita) in the USA (2002): 0.24, Calculated removal (%): 73.4, For the treatment of asthma and chronic obstructive pulmonary disease (COPD)., Use Classification: Pharmaceuticals, Methods of Manufacturing: Preparation: I.F. Skidmore et al., DE 3414752, eidem US 4992474 (1984, 1991 both to Glaxo), Formulations, Preparations: Oral Inhalation: Aerosol 21 ug (of salmeterol) per metered spray (from the actuator) Serevent ( with fluorochlorohydrocarbon propellants), (GlaxoSmithKline), Powder: 50 ug (of salmeterol) per inhalation Serevent Diskus, (GlaxoSmithKline)., Salmeterol xinafoate, Oral Inhalation: Powder 50 ug (of salmeterol) with fluticasone propionate 100, 250, or 500 ug per inhalation- Advair (GlaxoSmithKline)., Salmeterol xinafoate combinations, General Manufacturing Information: Structural analog of albuterol., Information available in 2005 indicated that Salmeterol was used in the manufacture of pharmaceutical preparations in the following countries: Antigua & Barbuda, Aruba, Bahrain, Barbados, Chile, Croatia, Grenada, Guyana, India, Iran, Jamaica, Kuwait, Luxembourg, Netherlands Antilles, Oman, Qatar, Saint Lucia, Saint Vincent & The Grenadines, Slovenia, Turkey, Trinidad & Tobago, United Arab Emirates, Yugoslavia (1, 2), Information available in 2005 indicated that Salmeterol xinafoate was used in the manufacture of pharmaceutical preparations in the following countries: Algeria, Argentina, Australia, Austria, Bangladesh, Belgium, Brazil, Bulgaria, Canada, Costa Rica, Czech Republic, Denmark, Dominican Republic, Ecuador, El Salvador, Finland, France, Germany, Greece, Guatemala, Honduras, Hong Kong, Hungary, Indonesia, Ireland, Israel, Italy, Malaysia, Mexico, Netherlands, New Zealand, Nicaragua, Norway, Panama, Poland, Portugal, Romania, Russian Federation, Singapore, South Africa, Spain, Sweden, Switzerland, Thailand, United Kingdom, United States (1.
Salmeterol is a carbon-based organic compound with CAS registry number 89365-50-4 and molecular formula C25H37NO4 (molecular weight 415.6), belonging to the organic chemicals segment of chemical raw materials.
CAS number: 89365-50-4
Its molecular formula C25H37NO4 comprises 25 C, 37 H, 1 N, 4 O atoms.
Also known as: Salmeterol · 沙美特罗
Category: organic chemicals
The CAS registry number of Salmeterol is 89365-50-4.
Molecular formula C25H37NO4, molecular weight 415.6.
It is also registered under: Salmeterol, 沙美特罗.
Recorded applications: Uses: Anti-asthmatic, Xinafoate salt, Bronchodilator, MEDICATION, Salmeterol ..., is, indicated as bronchodilators for the treatment of bronchospasm associated with chronic obstructive airway disease, including bronchitis and pulmonary emphysema. ..., Included in US product labeling, Use (kg, approx.) in Germany (2009): >10, Use (kg) in USA (2002): 67800, Consumption (g per capita, approx.) in Germany (2009): 0.000122, Consumption (g per capita) in the USA (2002): 0.24, Calculated removal (%): 73.4, For the treatment of asthma and chronic obstructive pulmonary disease (COPD)., Use Classification: Pharmaceuticals, Methods of Manufacturing: Preparation: I.F. Skidmore et al., DE 3414752, eidem US 4992474 (1984, 1991 both to Glaxo), Formulations, Preparations: Oral Inhalation: Aerosol 21 ug (of salmeterol) per metered spray (from the actuator) Serevent ( with fluorochlorohydrocarbon propellants), (GlaxoSmithKline), Powder: 50 ug (of salmeterol) per inhalation Serevent Diskus, (GlaxoSmithKline)., Salmeterol xinafoate, Oral Inhalation: Powder 50 ug (of salmeterol) with fluticasone propionate 100, 250, or 500 ug per inhalation- Advair (GlaxoSmithKline)., Salmeterol xinafoate combinations, General Manufacturing Information: Structural analog of albuterol., Information available in 2005 indicated that Salmeterol was used in the manufacture of pharmaceutical preparations in the following countries: Antigua & Barbuda, Aruba, Bahrain, Barbados, Chile, Croatia, Grenada, Guyana, India, Iran, Jamaica, Kuwait, Luxembourg, Netherlands Antilles, Oman, Qatar, Saint Lucia, Saint Vincent & The Grenadines, Slovenia, Turkey, Trinidad & Tobago, United Arab Emirates, Yugoslavia (1, 2), Information available in 2005 indicated that Salmeterol xinafoate was used in the manufacture of pharmaceutical preparations in the following countries: Algeria, Argentina, Australia, Austria, Bangladesh, Belgium, Brazil, Bulgaria, Canada, Costa Rica, Czech Republic, Denmark, Dominican Republic, Ecuador, El Salvador, Finland, France, Germany, Greece, Guatemala, Honduras, Hong Kong, Hungary, Indonesia, Ireland, Israel, Italy, Malaysia, Mexico, Netherlands, New Zealand, Nicaragua, Norway, Panama, Poland, Portugal, Romania, Russian Federation, Singapore, South Africa, Spain, Sweden, Switzerland, Thailand, United Kingdom, United States (1.
Category: Organic Chemicals.
Independent reference data for Salmeterol (CAS 89365-50-4), compiled from public chemistry databases.
| CAS Registry Number | 89365-50-4 |
|---|---|
| PubChem CID | 5152 |
| Molecular formula | C25H37NO4 |
| IUPAC name | 2-(hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl]phenol |
| UNII (FDA) | 2I4BC502BT |
| Molecular Weight | 415.6 |
|---|---|
| XLogP3 | 3.9 |
| Hydrogen Bond Donor Count | 4 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 16 |
| Exact Mass | 415.27225866 |
| Monoisotopic Mass | 415.27225866 |
| Topological Polar Surface Area | 82 |
| Heavy Atom Count | 30 |
| Boiling Point | 603 |
|---|---|
| Melting Point | 75.5-76.5 °C |
| Melting Point | 75.7-76.5 °C |
| Melting Point | 75.5 - 76.5 °C |
| Solubility | 2.26e-03 g/L |
| LogP | 4.2 |
Salmeterol; 89365-50-4; 2-(hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl]phenol; Salmeterolum; GR 33343X; SALMATEROL; SN408D; DTXSID6023571; GR 33343 X; 2I4BC502BT; GR-33343-X; DTXCID803571; 4-(1-hydroxy-2-((6-(4-phenylbutoxy)hexyl)amino)ethyl)-2-(hydroxymethyl)phenol; 4-(1-hydroxy-2-{[6-(4-phenylbutoxy)hexyl]amino}ethyl)-2-(hydroxymethyl)phenol; Neovent; Soltel
| Reported hazard statements | H302 (50%), H315 (100%), H317 (50%), H319 (100%), H412 (50%) |
|---|
H302 (50%): Harmful if swallowed [Warning Acute toxicity, oral]
H315 (100%): Causes skin irritation [Warning Skin corrosion/irritation]
Salmeterol · CAS 89365-50-4 · C25H37NO4. UNII 2I4BC502BT. Boiling Point: 603; Melting Point: 75.5-76.5 °C; Melting Point: 75.7-76.5 °C.
Source: PubChem / Wikidata; the batch COA governs where values differ.
Supplier: Jinan Shenghe Chemical Co., Ltd.
中文页面: 沙美特罗